Page last updated: 2024-08-05 11:51:19
cyclopentanes
Cyclopentane and its derivatives formed by substitution.
ChEBI ID: 23493
Members (6)
Member | Definition | Role |
---|---|---|
1-(1-phenylcyclopentyl)methylamine | 1-(1-phenylcyclopentyl)methylamine | |
b 43 | A member of the class of pyrrolopyrimidines that is 7H-pyrrolo[2,3-d]pyrimidine substituted by amino, 4-phenoxyphenyl, and cyclopentyl groups at positions 4, 5 and 7, respectively. It is a potent inhibitor of Lck that inhibits Lck (64-509) and LckCD isoforms (IC50 of less than 1 and 2 nM, respectively). | RK-24466 |
cyclopentane | A cycloalkane that consists of five carbons each bonded with two hydrogens above and below the plane. The parent of the class of cyclopentanes. | cyclopentane |
N-([biphenyl]-2-yl)-3-cyclopentylpropanamide | A secondary carboxamide resulting from the formal condensation of the carboxy group of 3-cyclopentylpropionic acid with the amino group of [biphenyl]-2-amine. | N-([biphenyl]-2-yl)-3-cyclopentylpropanamide |
palbociclib | A member of the class of pyridopyrimidines that is 2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7-one bearing additional methyl, acetyl and cyclopentyl substituents at positions 5, 6 and 8 respectively. It is used in combination with letrozole for the treatment of metastatic breast cancer. | palbociclib |
PP121 | A pyrazolopyrimidine that is 1H-pyrazolo[3,4-d]pyrimidine which is substituted by a cyclopentyl, 1H-pyrrolo[2,3-b]pyridin-5-yl, and amino groups at positions 1, 3 and 4, respectively. It is a dual inhibitor of tyrosine and phosphoinositide kinases and exhibits anti-cancer properties. | PP121 |
Research
Studies (11,215)
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 908 (8.10) | 18.7374 |
1990's | 1,212 (10.81) | 18.2507 |
2000's | 2,569 (22.91) | 29.6817 |
2010's | 4,951 (44.15) | 24.3611 |
2020's | 1,575 (14.04) | 2.80 |
Study Types
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 212 (1.85%) | 5.53% |
Reviews | 673 (5.87%) | 6.00% |
Case Studies | 91 (0.79%) | 4.05% |
Observational | 19 (0.17%) | 0.25% |
Other | 10,469 (91.32%) | 84.16% |